<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813370</url>
  </required_header>
  <id_info>
    <org_study_id>12-225</org_study_id>
    <nct_id>NCT01813370</nct_id>
  </id_info>
  <brief_title>A Registry for Patients Treated on the Clinical Trial TAX 3503</brief_title>
  <official_title>A Registry for Patients Treated on the Clinical Trial TAX 3503 (A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Montreal – Hospital Notre-Dame</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CancerCare Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tom Baker Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Urocentrum Praha s.r.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fakultní nemocnice Na Bulovce</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Jablonec nad Nisou, p.o</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klaipėda University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Institute of Vilnius University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fakultna Nemocnica s poliklinikou J.A. Reimana Presov, Klinika urologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martinska Fakultna Nemocnica, Urologicke klinika</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fakultna nemocnica s poliklinikou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BratislavaNemocnica ak. L Derera, Urologicka klinika</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Urologic Consultants of Southeastern PA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GU Research Network, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carolina Urologic Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lancaster Urology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansas City Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Urology San Antonio Research PA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Alexius Medical Center Clinical Research Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanguard Urologic Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Urological Institute of Northeastern NY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Urology Associates Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Sabadell</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Bernardino Urological Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbus Urology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Niepubliczny Specjalistyczny Onkologiczny Zaklad Opienki Zdrowotnej</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vinzenzkrankenhaus Hannover, Urologische Abteilung (Uro-Onkologie)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to continue follow-up on patients who were treated on the study
      called TAX 3505 (MSK IRB #07-101). The sponsor of this study, has decided to end the study
      early, before all patients have completed all planned follow-up tests. As a result, the
      investigators do not yet know whether hormonal therapy alone, or in combination with
      docetaxel, is better at preventing prostate cancer recurrence in patients who had a rising
      PSA after prostatectomy. This study will continue following patients according to a schedule
      that is similar to that found in the TAX 3503 (MSK IRB #07-101) study in order to answer that
      question. This study is known as a registry study. The patients' will not receive any
      treatment as part of this study. Instead, they will be asked to have a blood test performed
      once every 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>For patients treated on TAX3503 that will enable the study to achieve its primary endpoint of comparing the efficacy of its treatment arms as determined by progression-free survival during the period from randomization to progression or death or last followup.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>annotating clinical outcomes</measure>
    <time_frame>1 year</time_frame>
    <description>To utilize this registry for the purposes of annotating clinical outcomes to the biospecimens collected under TAX3503.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival differences</measure>
    <time_frame>1 year</time_frame>
    <description>Between the two arms</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Pts with prostate cancer</arm_group_label>
    <description>Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.</description>
    <arm_group_label>Pts with prostate cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum PSA evaluations Serum testosterone levels
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are presently on TAX3503 and undergoing followup for evidence of progressive
        disease will be approached by their study physicians at their local sites to enter the
        registry. No other patient will be approached or recruited. Some sites that were part of
        the TAX3503 study are unable to open this registry at their site. In order to minimize the
        number of participants whose information might be lost, Memorial Sloan-Kettering Cancer
        Center (MSKCC) will inform these sites that they may refer their participants to MSKCC for
        this registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The registry will include the database of all patients registered to TAX3503. Those
             patients who will be prospectively tracked through the registry are those who meet the
             following criteria:

               1. The patient must have been registered to TAX3503

               2. The patient must not have met the definition of progression as defined in TAX3503
                  while on TAX3503 Patients who have progressed or hit their 36 month post
                  treatment date between the closure of TAX3503 and the activation of this TAX3503
                  Registry protocol will be permitted on the study to capture their date of
                  progression or their 36 month post treatment progression free date.

        Exclusion Criteria:

          -  Patients who were not registered to TAX3503 are not eligible to have their data stored
             in this registry.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urological Associates of Lancaster</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29579</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University Health Sciences Kauno Klinikos</name>
      <address>
        <city>Kauno</city>
        <state>Klinikos</state>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Lithuania</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAX 3503</keyword>
  <keyword>MSKCC IRB#07-101</keyword>
  <keyword>12-225</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

